TABLE 1

Agonist activity for inhibiting forskolin stimulated cAMP accumulation in CHO M4 cells The data are from Fig. 2, a and b. The data represent the mean estimates ± S.E.M. The values in parentheses to the right of some of the estimates are the Log mean ± S.E.M.


Agonist

Emax a

EC50

Hill Slope

RAi
Null
Operational
% μM
Oxotremorine-M 82 ± 2.4 0.030 (–7.52 ± 0.07) 0.84 ± 0.10 5.79 (0.76 ± 0.07) 6.61 (0.82 ± 0.07)
Carbachol 88 ± 2.1 0.23 (–6.63 ± 0.05) 0.76 ± 0.06 1.0 (0.0) 1.0 (0.0)
McN-A-343 80 ± 6.6 0.56 (–6.25 ± 0.17) 0.65 ± 0.13 0.49 (–0.31 ± 0.12) 0.63 (–0.20 ± 0.12)
S-Aceclidine 87 ± 5.5 0.37 (–6.43 ± 0.14) 0.60 ± 0.09 0.98 (–0.0074 ± 0.20) 1.00 (0.0044 ± 0.10)
R-Aceclidine 71 ± 9.1 5.74 (–5.24 ± 0.26) 0.61 ± 0.15 0.071 (–1.50 ± 0.09) 0.040 (–1.36 ± 0.04)
Arecoline 65 ± 3.7 0.13 (–6.88 ± 0.09) 1.10 ± 0.07 0.68 (–0.17 ± 0.10) 0.73 (–0.14 ± 0.15)
Pilocarpine
83 ± 5.8
9.75 (–5.01 ± 0.12)
0.88 ± 0.10
0.013 (–1.89 ± 0.13)
0.013 (–1.87 ± 0.15)
  • a Denotes the maximal inhibition of forskolin-stimulated cAMP accumulation